GlassScriptPhysician profile
Laurence E Stawick
NPI 1710953914
$9,802.32
in general payments reported to CMS, 2019-2025
27 companies · $1,350 in 2025
The $1,350 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,556 · 2020: $1,521 · 2021: $1,299 · 2022: $561 · 2023: $1,304 · 2024: $1,211 · 2025: $1,350.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,865.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,865.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,551.40 | 2019-2025 | Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $1,513.12 | 2019-2025 | Tremfya, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $998.02 | 2019-2024 | Xifaxan |
| Gilead Sciences, INC. | $860.49 | 2019-2025 | Epclusa |
| Takeda Pharmaceuticals U.S.A., INC. | $839.34 | 2019-2025 | Entyvio |
| Qol Medical, LLC | $667.14 | 2019-2025 | Sucraid, Sucraid |
| Janssen Scientific Affairs, LLC | $386.84 | 2019-2025 | Tremfya, Stelara |
| E.R. Squibb & Sons, L.L.C. | $356.98 | 2021-2023 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $314.69 | 2023-2025 | Dupixent |
| Genzyme Corporation | $225.57 | 2023-2024 | |
| Aimmune Therapeutics, INC. | $225.47 | 2024-2025 | Zenpep |
| Ardelyx, INC. | $130.20 | 2023 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $118.35 | 2019-2020 | |
| Intercept Pharmaceuticals, INC. | $116.19 | 2022 | |
| Boston Scientific Corporation | $112.39 | 2024 | Axios |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $65.85 | 2020-2021 | |
| Ucb, INC. | $61.94 | 2019 | |
| Pfizer INC. | $40.87 | 2019 | |
| Welch Allyn | $34.46 | 2019 | |
| Alexion Pharmaceuticals, INC. | $31.47 | 2019 | |
| Allergan, INC. | $30.37 | 2019 | |
| Merck Sharp & Dohme LLC | $26.94 | 2019-2021 | |
| Braintree Laboratories, INC. | $22.81 | 2019 | |
| Ambu INC. | $20.60 | 2020 | |
| Medtronic USA, INC. | $18.82 | 2019 | |
| Celgene Corporation | $18.79 | 2021 | |
| Evoke Pharma, INC. | $13.21 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laurence Stawick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.